Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of the antifungal Cresemba® (isavuconazole) in Japan exceeded the threshold triggering the first sales milestone payment from its partner Asahi Kasei Pharma (AKP), amounting to approximately CHF 1.2 million. David Veitch, Chief Executive Officer of Basilea, said: “Japan is a key market

February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world’s first and only chikungunya vaccine, IXCHIQ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older. The vaccine is manufactured

Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection TNX-1500 blocked the primary and secondary antibody responses to a test antigen at the 10 mg/kg and 30 mg/kg i.v. doses TNX-1500 showed mean half-life of 34-38 days for the 10 mg/kg and 30 mg/kg doses supporting monthly dosing for future efficacy trials TNX-1500 was generally well-tolerated with a favorable safety profile Anti-CD40L has multiple pot

Agreement drives continued patient access to four important therapies in Japan and Korea Strengthens Essential Pharma and Clinigen’s combined market presence in the JAPAC region 6th February 2025 – Essential Pharma (“Essential” or “the Company”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, and Clinigen, the global specialty pharmaceutical services group,

Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting toxicities Enrollment for Phase 2 expected to commence imminently Feb. 05, 2025 - AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Safety Committee approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) a

-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five -- -- Com

Feb. 05, 2025 -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced an expanded agreement with Greenstone Biosciences Inc. (“Greenstone”) to leverage Artificial Intelligence (AI) in further developing its human induced pluripotent stem cell (iPSC) platform for diabetes treatment.This strategic collaboration extends the progress made on Creative Medical’s proprietary hy

Feb. 05, 2025 -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases, today announced that it has dosed its first patient in a Phase 2 clinical trial of Modified Atrial Natriuretic Peptide (MANP) for the treatment of Resistant Hypertension (BOLD-HTN). MANP was originally discovered by John C. Burnett Jr., MD, Director of the Cardiorenal Research Laboratory at Mayo Clinic. E-Star and Mayo Cl

Feb. 05, 2025 -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD. "The launch of our highly anticipated AD study is a significant milestone in advancing buntanetap toward mark

Feb. 05, 2025 -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand its ongoing U.S. clinical trial, INDP-D101, to Canadian sites, broadening patient recruitment and enhancing its